AI Stock Finder
Loading...
Skip to main content
Model output · Signal date Oct. 15, 2026

Daily Signals

2696 companies scored · 2026-10-15 run in progress: 5121 of ~5380 signals so far · Alpha · vs marketSwitch to Total · 30D 90D

Signal date 2026-10-15 Cut-offs from the 2026-10-15 run
Companies scored 2696 IC ≥ 0 · market cap ≥ $100M
Median forecast -0.28% Alpha · 90D
Long–short spread +5.12% Strong Buy minus Strong Sell, mean
Median IC 0.28 Spearman · 90D
Rating changes ▲ 545 ▼ 698 vs the previous run
Cross-section

Distribution of the day's forecasts

90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).

Signals · All

304 companies

Sorted by market cap ↓ · forecast rankings are part of the paid plans

# Ticker Sector IC Mkt cap Rating 30D 90D Δ
101 PRGOPERRIGO Co plc Life Sciences 0.67 $2.2B Unlock rating and forecasts
102 AUPHAurinia Pharmaceuticals Inc. Life Sciences 0.13 $2.2B Neutral -0.40% -0.86% ·
103 BHCBausch Health Companies Inc. Life Sciences 0.49 $2.2B Neutral -0.26% -0.49% ·
104 CLDXCelldex Therapeutics, Inc. Life Sciences 0.15 $2.2B Unlock rating and forecasts
105 HRMYHarmony Biosciences Holdings, Inc. Life Sciences 0.49 $2.2B Unlock rating and forecasts
106 NVAXNOVAVAX INC Life Sciences 0.13 $2.1B Unlock rating and forecasts
107 VRDNViridian Therapeutics, Inc.\DE Life Sciences 0.50 $2.1B Unlock rating and forecasts
108 VCELVericel Corp Life Sciences 0.27 $2.1B Unlock rating and forecasts
109 BCRXBIOCRYST PHARMACEUTICALS INC Life Sciences 0.24 $2.1B Unlock rating and forecasts
110 IMNMImmunome Inc. Life Sciences 0.22 $2.0B Unlock rating and forecasts
111 LKFTLakefront Biotherapeutics NV Life Sciences 0.39 $1.9B Neutral -0.28% -0.55% ▲ 1
112 AGIOAGIOS PHARMACEUTICALS, INC. Life Sciences 0.15 $1.9B Neutral -0.07% -0.10% ·
113 VERAVera Therapeutics, Inc. Life Sciences 0.10 $1.9B Unlock rating and forecasts
114 TRLVTrulieve Cannabis Corp. Life Sciences 0.08 $1.9B Unlock rating and forecasts
115 ALVOAlvotech Life Sciences 0.16 $1.9B Unlock rating and forecasts
116 SDGRSchrodinger, Inc. Life Sciences 0.45 $1.9B Unlock rating and forecasts
117 XTLBXTL BIOPHARMACEUTICALS LTD Life Sciences 0.14 $1.9B Neutral +0.23% -0.05% new
118 MLYSMineralys Therapeutics, Inc. Life Sciences 0.24 $1.8B Unlock rating and forecasts
119 PVLAPALVELLA THERAPEUTICS, INC. Life Sciences 0.12 $1.8B Unlock rating and forecasts
120 URGNUroGen Pharma Ltd. Life Sciences 0.41 $1.8B Unlock rating and forecasts
121 XERSXeris Biopharma Holdings, Inc. Life Sciences 0.10 $1.8B Unlock rating and forecasts
122 SRPTSarepta Therapeutics, Inc. Life Sciences 0.24 $1.8B Unlock rating and forecasts
123 VIRVir Biotechnology, Inc. Life Sciences 0.53 $1.8B Unlock rating and forecasts
124 XNCRXencor Inc Life Sciences 0.48 $1.7B Unlock rating and forecasts
125 TRVITrevi Therapeutics, Inc. Life Sciences 0.32 $1.7B Unlock rating and forecasts
126 MRVIMARAVAI LIFESCIENCES HOLDINGS, INC. Life Sciences 0.67 $1.7B Unlock rating and forecasts
127 ANIPANI PHARMACEUTICALS INC Life Sciences 0.59 $1.7B Unlock rating and forecasts
128 NUVBNuvation Bio Inc. Life Sciences 0.10 $1.6B Unlock rating and forecasts
129 ZBIOZenas BioPharma, Inc. Life Sciences 0.17 $1.6B Unlock rating and forecasts
130 GPCRStructure Therapeutics Inc. Life Sciences 0.00 $1.6B Unlock rating and forecasts
131 GENBGenerate Biomedicines, Inc. Life Sciences 0.19 $1.6B Unlock rating and forecasts
132 NTLAIntellia Therapeutics, Inc. Life Sciences 0.43 $1.6B Unlock rating and forecasts
133 OCULOCULAR THERAPEUTIX, INC Life Sciences 0.09 $1.6B Unlock rating and forecasts
134 CMPSCOMPASS Pathways plc Life Sciences 0.35 $1.6B Unlock rating and forecasts
135 PAHCPHIBRO ANIMAL HEALTH CORP Life Sciences 0.32 $1.5B Unlock rating and forecasts
136 QUREuniQure N.V. Life Sciences 0.10 $1.5B Unlock rating and forecasts
137 INVAInnoviva, Inc. Life Sciences 0.07 $1.5B Neutral -0.22% -0.41% ▲ 1
138 ETONEton Pharmaceuticals, Inc. Life Sciences 0.10 $1.5B Unlock rating and forecasts
139 STOKStoke Therapeutics, Inc. Life Sciences 0.40 $1.5B Unlock rating and forecasts
140 RAREUltragenyx Pharmaceutical Inc. Life Sciences 0.14 $1.5B Unlock rating and forecasts
141 ANABANAPTYSBIO, INC Life Sciences 0.27 $1.5B Neutral +0.08% +0.19% ·
142 PCRXPacira BioSciences, Inc. Life Sciences 0.25 $1.5B Neutral -0.26% -0.51% ·
143 COAGHemab Therapeutics Holdings, Inc. Life Sciences 0.46 $1.4B Unlock rating and forecasts
144 RAPPRapport Therapeutics, Inc. Life Sciences 0.04 $1.4B Unlock rating and forecasts
145 OMEROMEROS CORP Life Sciences 0.16 $1.3B Neutral -0.38% -0.81% ·
146 OPKOPKO HEALTH, INC. Life Sciences 0.35 $1.2B Unlock rating and forecasts
147 GHRSGH Research PLC Life Sciences 0.25 $1.2B Unlock rating and forecasts
148 BCAXBicara Therapeutics Inc. Life Sciences 0.20 $1.1B Unlock rating and forecasts
149 TSHATaysha Gene Therapies, Inc. Life Sciences 0.18 $1.1B Unlock rating and forecasts
150 AMPHAmphastar Pharmaceuticals, Inc. Life Sciences 0.40 $1.1B Neutral -0.31% -0.63% ·
101–150 of 304 Previous Next
Since the previous run

Rating changes

▲ 545▼ 698
Which companies were upgraded or downgraded is part of the paid plans.
Next step

Unlock the full ranking

Every company's rating, its 30- and 90-day forecasts, the forecast and IC-weighted rankings, the daily rating changes and CSV export.

See plans Create a free account
Methodology

Ratings are relative: the forecasts of the latest complete daily run (2026-10-15) are ranked and cut at the 15th, 35th, 65th and 85th percentiles, so Strong Sell is the bottom 15%, Sell the next 20%, Neutral the middle 30%, Buy the next 20% and Strong Buy the top 15%. Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. IC is the company's Spearman information coefficient between its past forecasts and the realised returns at the selected horizon; IC-weighted ranking multiplies each forecast by its IC (negative IC counts as zero). Δ is the rating move since the company's previous signal, in rating steps. Each company shows its latest signal, including one from a run still in progress; every signal is rated against the cut-offs above. Quantitative research output, not investment advice.